AI Article Synopsis

  • The EMPACT-MI trial is assessing the safety and effectiveness of empagliflozin in patients who have experienced an acute myocardial infarction and are at high risk for developing heart failure.
  • The study involves 5,000 participants from around the world, being randomized to receive either empagliflozin or a placebo, alongside standard medical care.
  • The trial aims to determine the impact of empagliflozin on preventing hospitalization for heart failure or reducing overall mortality in this patient population.

Article Abstract

Background: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven to improve outcomes in patients with HF with reduced ejection fraction, and, in the case of empagliflozin, in HF with preserved ejection fraction even without diabetes, but their efficacy and safety in the post-MI population has not yet been evaluated.

Methods: The EMPACT-MI trial will evaluate the safety and efficacy of empagliflozin compared with placebo in patients hospitalized for MI with or at high risk of new onset HF, in addition to standard care. EMPACT-MI is a streamlined, multinational, randomized, double-blind, placebo-controlled trial randomizing 5,000 participants at approximately 480 centers in 22 countries. Eligible patients presenting with spontaneous MI must have new signs or symptoms of pulmonary congestion requiring treatment or new left ventricular dysfunction (LVEF<45%), and at least 1 additional risk factor for development of future HF. Eligible and consenting patients are randomized to empagliflozin 10mg or placebo daily in addition to standard of care within 14 days of hospital admission for MI. The primary composite end point is time to first hospitalization for HF or all-cause mortality.

Conclusions: EMPACT-MI will inform clinical practice regarding the role of empagliflozin in patients after an MI with high-risk for the development of future HF and mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2022.05.010DOI Listing

Publication Analysis

Top Keywords

myocardial infarction
8
empact-mi trial
8
ejection fraction
8
empagliflozin patients
4
patients post
4
post myocardial
4
infarction rationale
4
rationale design
4
design empact-mi
4
trial background
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!